University of California San Francisco

Biography

Dr. Rita Mukhtar specializes in breast surgery and general surgery for urgent conditions. For her patients with breast cancer, she offers expertise in total skin-sparing mastectomies, breast conservation, wire localization surgery (used to show the location of tissue requiring biopsy) and sentinel lymph node biopsy (used to see if cancer has spread).

Dr. Mukhtar's research program focuses on invasive lobular carcinoma, the second most common type of breast cancer. This work is funded by the American Cancer Society and the National Cancer Institute. She teaches medical students and residents, and serves as an Associate Program Director for the UCSF General Surgery Residency.

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2018
University of California, San Francisco M.D. Medicine 2006

Board Certifications

American Board of Surgery, General Surgery

Clinical Expertise

Breast Surgery

Lumpectomy

Seed and wire localization surgery

Nipple sparing/total skin sparing mastectomy

Sentinel lymph node biopsy

Axillary dissection

Emergency General Surgery

Clinical Trials

  1. Related Conditions: Breast Cancer| Start Date: | End Date:
  2. Related Conditions: Breast Cancer| Start Date: | End Date:
  3. Related Conditions: Breast Cancer| Start Date: | End Date:
  4. Related Conditions: Breast Cancer, Carcinoma| Start Date: | End Date:

Program Affiliations

Carol Franc Buck Breast Care Center

In the News

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 172
  1. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    Alison S Baskin, Anne K Patterson, Amie M Blanco, Julie S Mak, Rita A Mukhtar| | UCSF Research Profile
  2. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA| | PubMed
  3. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    Tasce Bongiovanni, Elizabeth Lancaster, Hannah Decker, Rita A. Mukhtar, Marisa Schwab, Jeanette Broering, Patricia O’Sullivan, Kenzo Hirose, Elizabeth Wick| | UCSF Research Profile
  4. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    Abel MK, Shui AM, Chien AJ, Rugo HS, Melisko M, Baehner F, Mukhtar RA| | PubMed
  5. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    Abel MK, Mukhtar RA| | PubMed
  6. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    Jason J. Northey, Yoshihiro Yui, Mary-Kate Hayward, Connor Stashko, FuiBoon Kai, Janna Mouw, Dhruv Thakar, Jonathon Lakins, Alastair Ironside, Susan Samson, Rita Mukhtar, E. Shelley Hwang, Valerie Weaver| | UCSF Research Profile
  7. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    Laura Ann Huppert, Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, Amy Jo Chien, Christina Yau, Denise M. Wolf, Donald A. Berry, Laura van 't Veer, Douglas Yee, Angela DeMichele, Laura Esserman| | UCSF Research Profile
  8. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    Mukhtar R, Symmans WF, Esserman LJ| | PubMed
  9. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    Greenberg AL, Sullins VF, Donahue TR, Sundaram VM, Saldinger PF, Divino CM, Anton NE, Stefanidis D, Reilly LM, Egan RJ, Beals CKJ, Riall TS, Duh QY, Mukhtar RA, Hirose K, Lebares CC| | PubMed
  10. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman| | UCSF Research Profile